0001104659-22-005555.txt : 20220119
0001104659-22-005555.hdr.sgml : 20220119
20220119181922
ACCESSION NUMBER: 0001104659-22-005555
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220114
FILED AS OF DATE: 20220119
DATE AS OF CHANGE: 20220119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mandelia Ashish
CENTRAL INDEX KEY: 0001782805
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38129
FILM NUMBER: 22540005
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mersana Therapeutics, Inc.
CENTRAL INDEX KEY: 0001442836
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-498-0020
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC
DATE OF NAME CHANGE: 20080813
4
1
tm223926-2_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-01-14
0
0001442836
Mersana Therapeutics, Inc.
MRSN
0001782805
Mandelia Ashish
C/O MERSANA THERAPEUTICS, INC.
840 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
0
1
0
0
VP, Controller
Common Stock
2022-01-14
4
M
0
5353
A
5353
D
Common Stock
2022-01-18
4
S
0
1982
5.92
D
3371
D
Restricted Stock Units
2022-01-14
4
M
0
833
0
D
Common Stock
833
1666
D
Restricted Stock Units
2022-01-14
4
M
0
4520
0
D
Common Stock
4520
13557
D
Stock Option (right to buy)
6.28
2022-01-14
4
A
0
28700
0
A
2032-01-13
Common Stock
28700
28700
D
Restricted Stock Units
2022-01-14
4
A
0
19133
0
A
Common Stock
19133
19133
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon vesting.
Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. These sales were mandated by the Issuer's election under its equity incentive plans to require the reporting person to sell a number of shares of common stock needed to satisfy his tax withholding obligations and does not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.83 to $5.92, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
50% of the total number of RSUs vested as of January 14, 2022, and thereafter shall vest in equal annual installments over the next two years.
25% of the total number of RSUs vested on January 14, 2022, and thereafter shall vest in equal annual installments over the next three years.
The option vests in equal quarterly installments over the first four years after the vesting commencement date, January 14, 2022.
The restricted stock units vest in equal annual installments over the first four years after the vesting commencement date, January 14, 2022.
/s/ Brian DeSchuytner, as Attorney-in-Fact
2022-01-19